Recently, two other phase III trials, namely CAPSTONE-1 and ASTRUM005, confirmed the benefit of immunotherapy plus CT in the first-line treatment of ES-SCLC patients by adding the anti-PD-L1 adebrelimab [8] and the anti-PD1 serplulimab [9], respectively. The gene discussed is CD274; the disease is small cell lung carcinoma.